Literature DB >> 25973066

Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma.

Chenggang Yang1, Yongchun Zhou2, Lijuan Zhang1, Congguo Jin2, Mei Li1, Lijuan Ye1.   

Abstract

Indoleamine 2, 3-dioxygenase (IDO) is a rate-limiting enzyme for tryptophan metabolism inducing immune tolerance of tumors. The purpose of this study is to investigate IDO expression and its prognostic significance in bladder urothelial carcinoma (BUC). In this study, immunohistochemical staining for IDO expression in BUC tissues (n = 84) and normal bladder tissues (n = 22) was performed. The mRNA expression levels of IDO in BUC and normal bladder were analyzed by quantitative RT-PCR. Survival analysis was performed for the correlation of IDO expression and clinicopathological factors with disease-free survival. Positive expression of IDO was found in 48 of 84 cases in BUC tissues and was significantly correlated with histological classification, histological grade and TNM stage. While IDO expression in normal bladder tissues was expressed in only 4 of 22 (18.2%) cases. Moreover, IDO mRNA levels of BUC were significantly higher than that of normal bladder. We also found that IDO, histological grade and TNM stage were closely associated with DFS. These results indicated that IDO was related to the progression of BUC and might be one of the crucial prognostic factors for BUC.

Entities:  

Keywords:  3-dioxygenase; Indoleamine 2; bladder urothelial carcinoma; disease-free survival; immunohistochemistry; prognosis

Mesh:

Substances:

Year:  2015        PMID: 25973066      PMCID: PMC4396304     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  29 in total

1.  Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer.

Authors:  Simonetta Astigiano; Barbara Morandi; Roberta Costa; Luca Mastracci; Antonella D'Agostino; Giovanni Battista Ratto; Giovanni Melioli; Guido Frumento
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

2.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Authors:  Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast
Journal:  Nat Med       Date:  2005-02-13       Impact factor: 53.440

Review 3.  Cancer invasion and metastasis.

Authors:  Christian Wittekind; Matthias Neid
Journal:  Oncology       Date:  2005-09-19       Impact factor: 2.935

Review 4.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

Authors:  Anirban P Mitra; Ram H Datar; Richard J Cote
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

5.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

6.  Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.

Authors:  Miho Takao; Aikou Okamoto; Takashi Nikaido; Mitsuyoshi Urashima; Satoshi Takakura; Misato Saito; Motoaki Saito; Sanshiro Okamoto; Osamu Takikawa; Hiroshi Sasaki; Makoto Yasuda; Kazunori Ochiai; Tadao Tanaka
Journal:  Oncol Rep       Date:  2007-06       Impact factor: 3.906

7.  Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase.

Authors:  O Takikawa; R Yoshida; R Kido; O Hayaishi
Journal:  J Biol Chem       Date:  1986-03-15       Impact factor: 5.157

8.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

Authors:  Gerald Brandacher; Alexander Perathoner; Ruth Ladurner; Stefan Schneeberger; Peter Obrist; Christiana Winkler; Ernst R Werner; Gabriele Werner-Felmayer; Helmut G Weiss; Georg Göbel; Raimund Margreiter; Alfred Königsrainer; Dietmar Fuchs; Albert Amberger
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

9.  Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.

Authors:  Agnes Witkiewicz; Timothy K Williams; Joseph Cozzitorto; Brandice Durkan; Shayna L Showalter; Charles J Yeo; Jonathan R Brody
Journal:  J Am Coll Surg       Date:  2008-03-04       Impact factor: 6.113

10.  Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.

Authors:  K Ino; N Yoshida; H Kajiyama; K Shibata; E Yamamoto; K Kidokoro; N Takahashi; M Terauchi; A Nawa; S Nomura; T Nagasaka; O Takikawa; F Kikkawa
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

View more
  7 in total

1.  Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

Authors:  Nick van Dijk; Samuel A Funt; Christian U Blank; Thomas Powles; Jonathan E Rosenberg; Michiel S van der Heijden
Journal:  Eur Urol       Date:  2018-09-28       Impact factor: 20.096

3.  Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions.

Authors:  John L Pfail; Andrew B Katims; Parissa Alerasool; John P Sfakianos
Journal:  World J Urol       Date:  2020-10-15       Impact factor: 4.226

Review 4.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

5.  Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.

Authors:  Tao Zhang; Xiang-Long Tan; Yong Xu; Zi-Zheng Wang; Chao-Hui Xiao; Rong Liu
Journal:  Chin Med J (Engl)       Date:  2017-03-20       Impact factor: 2.628

6.  Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder.

Authors:  Donghyun Kim; Jin Man Kim; Jun-Sang Kim; Sup Kim; Kyung-Hee Kim
Journal:  J Clin Med       Date:  2020-04-27       Impact factor: 4.241

7.  Indoleamine 2,3-Dioxygenase-1 Expression is Changed During Bladder Cancer Cell Invasion.

Authors:  Hellen Joyce Sousa Pereira Santos; Luiz Henrique Gomes Matheus; Aline Silva; Stephanie Vanin Dalmazzo; Andressa Assunção Santos; Letícia Rafaela Alves Rubens Santos; Diego Mota Souza; Sabrina Thalita Reis; Ivan Pereira Nascimento; Humberto Dellê
Journal:  Int J Tryptophan Res       Date:  2022-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.